ArticleACS synthetic biology2026
A Framework for the In Vivo Production of Extensively Engineered Thiopeptides.
Article in ACS synthetic biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Thiopeptides are a family of macrocycle-containing ribosomally synthesized and post-translationally modified peptides. Their elaborate scaffolds offer considerable potential for bioengineering toward thiopeptide-based pharmaceuticals and other practical applications. Among thiopeptides, lactazoles possess uniquely promiscuous biosynthetic machinery that enables the creation of diverse macrocyclic peptides. Previous bioengineering efforts have exploited this machinery to achieve the de novo design of bioactive lactazole-based thiopeptides in vitro. However, it remains unclear whether microbial systems can produce lactazole-based thiopeptides with dramatically engineered macrocycles, particularly those that are expanded and contain more than 50% amino acid divergence relative to native lactazole macrocycles. Here, we established a framework for the in vivo production of lactazole-based thiopeptides by tuning expression cassettes and selecting suitable heterologous hosts and culture conditions. Initially, we focused on transcriptional terminators in the 3'-untranslated region of the precursor gene and identified the lazA terminator as a critical determinant for lactazole production. We then evaluated several heterologous Streptomyces hosts and selected Streptomyces sp. TP-A0584 ΔgodA for the production of lactazole-based thiopeptides. Under optimized conditions, including low-temperature cultivation, more than 90% of the tested lactazole-based thiopeptides were successfully produced, and a large part of them reached mg-scale production, with a maximum titer of 46.4 mg/L. Notably, although their macrocycles showed up to 73% amino acid divergence from those of native lactazoles, most of these lactazole-based thiopeptides were successfully produced in vivo. Our framework represents an initial step toward enabling the large-scale supply of lactazole-based thiopeptides and should facilitate the development of thiopeptide-based bioactive molecules.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.